Related Experiment Video
Updated: Feb 23, 2026
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
Transforming Growth Factor Beta is regulated by a Glucocorticoid-Dependent Mechanism in Denervation Mouse Bone
Ye Li1, Ligang Jie2, Austin Y Tian3
1School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Abstract:
Bone growth and remodeling is inhibited by denervation in adults and children, resulting in alterations of linear growth and bone mass and increased risk for osteoporosis and pathologic fractures. Transforming growth factor beta (TGF-β) isoforms are a key group of growth factors that enhance bone formation. To explore the relation between denervation-induced reduction of bone formation and TGF-β gene expression, we measured mRNA levels of TGF-β in denervation mouse bone and found decreased mRNA levels of TGF-β1, TGF-β2 and TGF-β3. These changes were accompanied by diminishing weight loss, bone mineral density (BMD), trabecular thickness, trabecular separation and trabecular number of femur and lumbar, serum osteocalcin, total calcium, intact parathyroid hormone, and increased serum C telopeptide. Recombinant human TGF-β1 (rhTGF-β1) prevented denervation-induced reduction of BMD further supporting our hypothesis that denervation-induced reduction of bone formation is a result of inhibition of TGF-β gene expression. In addition, antiprogestins RU 38486 blunted the denervation-induced decrease in mRNA levels of TGF-β group, while dexamethasone (DEX) decreased TGF-β group mRNA levels in normal mice. Furthermore, the denervated-mice exhibited a threefold increase in plasma corticosterone. These results suggest that denervation-induced reduction of bone formation may be regulated by glucocorticoids via inhibition of TGF-β gene expression at least in part.
Insights
Denervation reduces bone formation by decreasing transforming growth factor beta (TGF-β) gene expression. Supplementation with TGF-β1 protein can prevent bone loss, suggesting a therapeutic target for denervation-induced osteoporosis.
Area of Science:
- Bone Biology
- Endocrinology
- Regenerative Medicine
Background:
- Denervation impairs bone growth and remodeling, increasing osteoporosis risk.
- Transforming growth factor beta (TGF-β) isoforms are crucial for bone formation.
Purpose of the Study:
- To investigate the link between denervation, reduced bone formation, and TGF-β gene expression.
- To explore potential regulatory mechanisms involving glucocorticoids.
Main Methods:
- Measured TGF-β mRNA levels in denervated mouse bone.
- Assessed bone mineral density (BMD), bone structure, and serum markers.
- Administered recombinant human TGF-β1 (rhTGF-β1), antiprogestins, and dexamethasone (DEX).
Main Results:
- Denervation decreased TGF-β1, TGF-β2, and TGF-β3 mRNA levels.
- Bone mass, density, and structural integrity were reduced post-denervation.
- rhTGF-β1 administration prevented denervation-induced BMD loss.
- Dexamethasone decreased TGF-β group mRNA levels and denervated mice showed increased corticosterone.
Conclusions:
- Denervation-induced bone loss is associated with suppressed TGF-β gene expression.
- Glucocorticoids may regulate bone formation during denervation by inhibiting TGF-β.
- TGF-β1 represents a potential therapeutic agent for denervation-related bone loss.
